The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sørlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 10,938
ELSTON, C. W., & ELLIS, I. O. (1991) · Histopathology · doi:10.1111/j.1365-2559.1991.tb00229.x · Cited by 6,175
Wolff, A. C., Hammond, M. E. H., Schwartz, J. N., Hagerty, K. L., Allred, D. C., Cote, R. J., Dowsett, M., Fitzgibbons, P. L., Hanna, W. M., Langer, A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2775 · Cited by 4,434
Harvey, J. M., Clark, G. M., Osborne, C. K., & Allred, D. C. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.5.1474 · Cited by 2,056
TIGAR, a p53-Inducible Regulator of Glycolysis and Apoptosis
Bensaad, K., Tsuruta, A., Selak, M. A., Vidal, M. N. C., Nakano, K., Bartrons, R., Gottlieb, E., & Vousden, K. H. (2006) · Cell · doi:10.1016/j.cell.2006.05.036 · Cited by 2,019
Wolff, A. C., Hammond, M. E. H., Schwartz, J. N., Hagerty, K. L., Allred, D. C., Cote, R. J., Dowsett, M., Fitzgibbons, P. L., Hanna, W. M., Langer, A., et al. (2007) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2007-131-18-asocco · Cited by 1,816
Pathological prognostic factors in breast cancer
Elston, C. (1999) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(99)00034-7 · Cited by 1,735
Prognostic markers in triple‐negative breast cancer
Rakha, E. A., El‐Sayed, M. E., Green, A. R., Lee, A. H. S., Robertson, J. F., & Ellis, I. O. (2007) · Cancer · doi:10.1002/cncr.22381 · Cited by 1,283
Revision of the American Joint Committee on Cancer Staging System for Breast Cancer
Singletary, S. E., Allred, C., Ashley, P., Bassett, L. W., Berry, D., Bland, K. I., Borgen, P. I., Clark, G., Edge, S. B., Hayes, D. F., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.02.026 · Cited by 1,173
Vousden, K. H., & Ryan, K. M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2715 · Cited by 959 · cited 1×
“Mutations of p53 were found to impair the repressive effect of p53 on GLUT1 and GLUT4 gene promoters [30, 31].”
BackgroundThe Tumor Suppressor p53 Down-Regulates Glucose Transporters GLUT1 and GLUT4 Gene Expression
Schwartzenberg-Bar-Yoseph, F., Armoni, M., & Karnieli, E. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-0846 · Cited by 726
Bos, R., van der Hoeven, J. J. M., van der Wall, E., van der Groep, P., van Diest, P. J., Comans, E. F. I., Joshi, U., Semenza, G. L., Hoekstra, O. S., Lammertsma, A. A., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.2.379 · Cited by 591
Avril, N., Rosé, C. A., Schelling, M., Dose, J., Kuhn, W., Bense, S., Weber, W., Ziegler, S., Graeff, H., & Schwaiger, M. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.20.3495 · Cited by 557
A simple p53 functional assay for screening cell lines, blood, and tumors.
Flaman, J. M., Frebourg, T., Moreau, V, Charbonnier, F., Martin, C., Chappuis, P., Sappino, A. P., Limacher, I. M., Bron, L., & Benhattar, J. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.9.3963 · Cited by 454
HER2 Status and Benefit from Adjuvant Trastuzumab in Breast Cancer
Paik, S., Kim, C., & Wolmark, N. (2008) · New England Journal of Medicine · doi:10.1056/nejmc0801440 · Cited by 426
Avril, N. E., Menzel, M. M., Dose, J., Schelling, M., Weber, W., Jänicke, F., NATHRATH, W. B. J., & Schwaiger, M. (2001) · PubMed · Cited by 414
Elston, C. W., & Ellis, I. O. (2002) · Histopathology · doi:10.1046/j.1365-2559.2002.14691.x · Cited by 380
FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters
Buck, A., Schirrmeister, H., Kühn, T., Shen, C., Kalker, T., Kotzerke, J., Dankerl, A., Glatting, G., Reske, S., & Mattfeldt, T. (2002) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-002-0880-8 · Cited by 305
Dehdashti, F., Mortimer, J. E., Siegel, B. A., et al. (1995) · PubMed · Cited by 290
Fuster, D., Duch, J., Paredes, P., Velasco, M., Muñoz, M., Santamaría, G., Fontanillas, M., & Pons, F. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.1496 · Cited by 280
Triple negative breast cancers: Clinical and prognostic implications
Dawson, S. J., Provenzano, E., & Caldas, C. (2009) · European Journal of Cancer · doi:10.1016/s0959-8049(09)70013-9 · Cited by 266
Basu, S., Chen, W., Tchou, J., Mavi, A., Cermik, T., Czerniecki, B., Schnall, M., & Alavi, A. (2008) · Cancer · doi:10.1002/cncr.23226 · Cited by 248
Ueda, S., Tsuda, H., Asakawa, H., Shigekawa, T., Fukatsu, K., Kondo, N., Yamamoto, M., Hama, Y., Tamura, K., Ishida, J., et al. (2008) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyn019 · Cited by 233
Oshida, M., Uno, K., Suzuki, M., Nagashima, T., Hashimoto, H., Yagata, H., Shishikura, T., Imazeki, K., & Nakajima, N. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980601)82:11<2227::aid-cncr18>3.0.co;2-w · Cited by 230
Clinicopathologic factors associated with false negative FDG–PET in primary breast cancer
Kumar, R., Chauhan, A., Zhuang, H., Chandra, P., Schnall, M., & Alavi, A. (2006) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9159-2 · Cited by 226
Jung, S.-Y., Kim, H. Y., Nam, B.-H., Min, S. Y., Lee, S. J., Park, C., Kwon, Y., Kim, E.-A., Ko, K. L., Shin, K. H., et al. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0780-8 · Cited by 215
[18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy
Berriolo-Riedinger, A., Touzery, C., Riedinger, J.-M., Toubeau, M., Coudert, B., Arnould, L., Boichot, C., Cochet, A., Fumoleau, P., & Brunotte, F. (2007) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-007-0459-5 · Cited by 180
Bertheau, P., Turpin, E., Rickman, D. S., Espié, M., de Reyniès, A., Feugeas, J.-P., Plassa, L.-F., Soliman, H., Varna, M., de Roquancourt, A., et al. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040090 · Cited by 173
Self-citationAssociation between [18F]fluorodeoxyglucose uptake and prognostic parameters in breast cancer
Gil-Rendo, A., Martínez-Regueira, F., Zornoza, G., García-Velloso, M. J., Beorlegui, C., & Rodriguez-Spiteri, N. (2009) · British Journal of Surgery · doi:10.1002/bjs.6459 · Cited by 173
Gene expression patterns associated with p53 status in breast cancer
Troester, M. A., Herschkowitz, J. I., Oh, D. S., He, X., Hoadley, K. A., Barbier, C. S., & Perou, C. M. (2006) · BMC Cancer · doi:10.1186/1471-2407-6-276 · Cited by 168
Manié, É., Vincent‐Salomon, A., Lehmann‐Che, J., Pierron, G., Turpin, E., Warcoin, M., Gruel, N., Lebigot, I., Sastre‐Garau, X., Lidereau, R., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-1560 · Cited by 163
Self-citationEffect of 18F-FDG PET/CT Imaging in Patients With Clinical Stage II and III Breast Cancer
Groheux, D., Moretti, J., Baillet, G. Y., et al. (2008) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2008.02.056 · Cited by 122
Self-citationBiological characterisation of breast cancer by means of PET
Buck, A. K., Schirrmeister, H., Mattfeldt, T., & Reske, S. N. (2004) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-004-1529-6 · Cited by 103
The relationship between FDG uptake in PET scans and biological behavior in breast cancer
Shimoda, W., Hayashi, M., Murakami, K., Oyama, T., & Sunagawa, M. (2007) · Breast Cancer · doi:10.2325/jbcs.14.260 · Cited by 101
Osborne, J. R., Port, E. R., Gönen, M., Doane, A. S., YEUNG, H. W. D., Gerald, W. L., Cook, J., & Larson, S. M. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.060459 · Cited by 92
Norberg, T., Lennerstrand, J., Inganäs, M., & Bergh, J. C. S. (1998) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19980821)79:4<376::aid-ijc12>3.0.co;2-3 · Cited by 57
Cited by
Positron Emission Tomography (PET) in Oncology
Gallamini, A., Zwarthoed, C., & Borra, A. (2014) · Cancers · doi:10.3390/cancers6041821 · Cited by 312
Performance of FDG PET/CT in the Clinical Management of Breast Cancer
Groheux, D., Espié, M., Giacchetti, S., & Hindié, E. (2013) · Radiology · doi:10.1148/radiol.12110853 · Cited by 271
Self-citationRole of Optimal Quantification of FDG PET Imaging in the Clinical Practice of Radiology
Ziai, P., Hayeri, M. R., Salei, A., Salavati, A., Houshmand, S., Alavi, A., & Teytelboym, O. M. (2016) · RadioGraphics · doi:10.1148/rg.2016150102 · Cited by 106
PET quantification: strategies for partial volume correction
Bettinardi, V., Castiglioni, I., De Bernardi, E., & Gilardi, M. C. (2014) · Clinical and Translational Imaging · doi:10.1007/s40336-014-0066-y · Cited by 105
Variation of liver SUV on 18FDG-PET/CT studies in women with breast cancer
Groheux, D., Delord, M., Rubello, D., Colletti, P. M., Nguyen, M.-L., & Hindié, E. (2013) · Clinical Nuclear Medicine · doi:10.1097/rlu.0b013e3182872f0e · Cited by 35
Self-citation
Metadata
- Authors
- Groheux, D., Giacchetti, S., Moretti, J.-L., Porcher, R., Espié, M., Lehmann-Che, J., de Roquancourt, A., Hamy, A.-S., Cuvier, C., Vercellino, L., & Hindié, E.
- Venue
- European Journal of Nuclear Medicine and Molecular Imaging
- Published
- 2010-11-06
- Volume
- 38
- Issue
- 3
- Pages
- 426-435
- ISSN
- 1619-7070 (ISSN-L)
- 1619-7089
- OpenAlex
- W2156681954
- Cited by
- 394
- References
- 36
- FWCI
- 15.19
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.